Assessing CLENPIQ for bowel preparation in children undergoing colonoscopy

A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years

This study is testing if CLENPIQ works better than MIRALAX to help kids aged 2 to under 9 get ready for a colonoscopy.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Ages: 2 Years to 8 Years
• Sex: All
• Sponsor: Ferring Pharmaceuticals (Industry-sponsored)
• Locations: 5 sites (Mobile, Alabama and 4 other locations)
• Trial ID: NCT04113382 on ClinicalTrials.gov

What this trial studies

This study evaluates the effectiveness of CLENPIQ as a bowel preparation method for pediatric patients scheduled for elective colonoscopy. It involves children aged 2 to less than 9 years who meet specific criteria regarding bowel movement frequency and weight. Participants will receive either CLENPIQ or MIRALAX to determine the best approach for ensuring adequate bowel cleansing prior to the procedure.

Who should consider this trial

Good fit: Ideal candidates are children aged 2 to less than 9 years who are scheduled for elective colonoscopy and have a history of regular bowel movements.

Not a fit: Patients with significant liver, cardiovascular, or renal diseases, or those with acute abdominal conditions will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could improve bowel preparation methods for children, leading to safer and more effective colonoscopy procedures.

How similar studies have performed: While there have been studies on bowel preparation in adults, this specific approach for pediatric patients using CLENPIQ is relatively novel.

Eligibility criteria

Inclusion Criteria:

* Male or female, aged 2 years to \<9 years being scheduled to undergo elective colonoscopy.
* Weight ≥10 kg (≥22 lbs).
* Participants must have had an average of three or more spontaneous bowel movements (SBM) per week for 1 month prior to the colonoscopy.
* Written informed consent (by parent(s)/ caregiver(s)/ guardian(s)) and assent (if applicable) obtained at screening.

Exclusion Criteria:

* History of significant liver, cardiovascular, or renal disease (including recent or ongoing oliguria).
* Acute surgical abdominal conditions (e.g., acute obstruction or perforation) during the screening period.
* Clinically significant abdominal pain during the screening period.
* Severe acute inflammatory bowel disease (IBD) during the screening period.
* Any prior colorectal surgery, excluding appendectomy and polyp removal.
* History of colon disease (e.g., Hirschsprung disease, volvulus, idiopathic pseudo-obstruction, or hypomotility syndrome).
* History of or ongoing intestinal ulceration, toxic megacolon or other toxic colitis.
* History of upper gastrointestinal disorder (e.g., active ulcer, pyloric stenosis or other cause of gastric retention, gastroparesis, or ileus).
* History of upper gastrointestinal surgery (e.g., gastric resection or gastric bypass), excluding cholecystectomy.
* Chronic or persistent, severe nausea or vomiting during the screening period.
* Moderate to severe dehydration during the screening period.
* Prior history of epileptic reaction, convulsions, or seizures.
* Any clinically relevant neurological events with or without association with hyponatremia during the screening period.
* Serum creatinine, estimated glomerular filtration rate (eGFR), potassium, or sodium outside normal limits during the screening period.
* Hypermagnesemia during the screening period.
* Use of the following prohibited medication: lithium (within 48 hours prior to procedure), laxatives (within 24 hours prior to procedure), drugs that in the opinion of the investigator are causing constipation in the participant (within 48 hours prior to procedure), antidiarrheal drugs (within 72 hours prior to procedure), or oral iron preparations (within 1 week prior to procedure).
* Participation in an interventional investigational trial requiring administration of an investigational drug within 30 days prior to receiving trial medication (or within 60 days for investigational drugs with an elimination half-life \>15 days).
* Any clinically relevant abnormal findings in medical history, physical examination, vital signs, electrocardiogram (ECG), clinical chemistry, hematology, coagulation, or urinalysis at screening which in the opinion of the investigator(s), might put the participant at risk because of his/her participation in the trial.
* Hypersensitivity to any of the ingredients of the trial medications.
* Inability to comply with the dietary restrictions in the trial or the fluid requirements before and after investigational medicinal product (IMP) administration.

Where this trial is running

Mobile, Alabama and 4 other locations

• Ferring Investigational Site — Mobile, Alabama, United States (Recruiting)
• Ferring Investigational Site — San Diego, California, United States (Recruiting)
• Ferring Investigational Site — Baltimore, Maryland, United States (Recruiting)
• Ferring Investigational Site — Baltimore, Maryland, United States (Recruiting)
• Ferring Investigational Site — The Bronx, New York, United States (Recruiting)

Study contacts

• Study coordinator: Global Clinical Compliance

Conditions Bowel Preparation; Colon Cleansing; Preparation for Colonoscopy